10 - 11 June 2025
Denver
More details come soon!
A multi-stakeholder Forum where all Stakeholders share information and discuss the strategy of new drug development with regards to their Mechanism of Action (MoA) to address unmet medical needs in a transparent scientific discussion
Q1/ Midst/ Q4 every year
2 live Paediatric Strategy Forums – 1 in Europe & 1 in US
To share information, to facilitate the development of innovative medicines and ultimately their introduction into the standard-of-care of children with malignancies
Agreement by all involved (industry and academia) based on scientific arguments
Which product, based on current evidence, is considered to have the highest potential to address unmet medical needs
The sequence in which other available (or emerging) products should be developed or deferred. So that as soon as a development is completed (either due to futility or efficacy) others are already prepared for evaluation
Engage regulatory agencies in a consolidated effort early in development
Monitoring changes in regulatory submissions and approvals both in Europe and the US (changing from adult-condition based waivers to scientifically and medically relevant waivers)
Publish results publicly via summaries and manuscripts